Bobby W. Sandage, Jr., Ph.D. has over 30 years of experience in the pharmaceutical industry. He has been President and CEO of Euclises Pharmaceuticals, Inc. since January 2015. Previously he was President and Chief Executive Officer for Coronado BioSciences, Inc. (CNDO) where he led the effort to take the company public 2011. Prior to that, he was vice president of Covidien (Mallinckrodt) Pharmaceuticals’ oncology research and development program. For 19 years, Dr. Sandage was the Chief Scientific Officer and Executive Vice President of research and development, quality and manufacturing at Indevus Pharmaceuticals, which was acquired by Endo Pharmaceuticals in 2009. Prior to Indevus he held senior drug development positions at DuPont Merck Pharmaceutical Company, DuPont/American Critical Care, Merrell Dow and Dow Pharmaceuticals.
Dr. Sandage is currently a director and chairman of Immunophotonics, a private oncology company, director at Tensive Controls, a private company focused on cachexia therapies and Mateon Therapeutics (MATN), a public oncology company. Previously he was director of Tioma (private oncology company) and director and chairman of the Scientific Committee of the Italian biotech company, Gentium (GENT). He was director and member of the audit committee for Osteologix, Inc. (OLGX), a director and a member of the audit committee of Genta Inc. (GNTA) and a director for the privately held company, Aeolus Pharmaceuticals, which was a subsidiary of Incara Pharmaceuticals.
Dr. Sandage is currently a member of the Southern Illinois University Edwardsville School of Pharmacy Advisory Board and a member of the University of Arkansas College of Pharmacy Dean’s Advisory Board. He is an adjunct Professor in the Department of Pharmaceutical Sciences at Southern Illinois University Edwardsville School of Pharmacy and has formerly held an appointment as adjunct professor in the Department of Pharmacology at the Massachusetts College of Pharmacy and has published over 50 scientific articles. He was a faculty member and lecturer for the Pharmaceutical Educational and Research Institute, Inc. regarding drug development.
Dr. Sandage received his Ph.D. in Clinical Pharmacy from Purdue University and his B.S. in Pharmacy from the University of Arkansas. Dr. Sandage is a registered pharmacist.